Lv31
324 积分 2022-09-05 加入
Primary central nervous system lymphoma
1小时前
待确认
Bruton’s tyrosine kinase inhibitor zanubrutinib-based regimens in relapsed/refractory primary diffuse large B-cell lymphoma of the central nervous system
1小时前
已完结
Outcomes of CD19 CAR‐T therapy in central nervous system lymphoma: Insights from a multicentre experience
1小时前
已完结
Central Nervous System Lymphoma
6天前
已完结
Zanubrutinib, Obinutuzumab, and Venetoclax for First-Line Treatment of Mantle Cell Lymphoma with a TP53 Mutation
16天前
已完结
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
18天前
已完结
Emerging biomarkers for CD3×CD20 bispecific antibodies in lymphoma
18天前
已完结
Frontline treatment of follicular lymphoma: What will it take to change current practice?
1个月前
已完结
End points and Outcomes in Follicular Lymphoma: What should we measure, how, and why?
1个月前
已完结
An Updated Understanding of Follicular Lymphoma Transformation
1个月前
已关闭
皖公网安备34019202002308
